Extended Data Table 4 Efficacy Data for Part 1 by Dosing Cohort

From: Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial

  1. CR, complete response; mOS, median overall survival; mPFS, median progression-free survival; NYR, not yet reached; ORR, overall response rate; PR, partial response; sCR, stringent complete response; VGPR, very good partial response.
Back to article page